| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ANP32A |
| Uniprot No | P39687 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-249aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMEMGRRIHLELRNRTPSDVKELVLDNSRSN EGKLEGLTDEFEELEFLSTINVGLTSIANLPKLNKLKKLELSDNRVSGGL EVLAEKCPNLTHLNLSGNKIKDLSTIEPLKKLENLKSLDLFNCEVTNLND YRENVFKLLPQLTYLDGYDRDDKEAPDSDAEGYVEGLDDEEEDEDEEEYD EDAQVVEDEEDEDEEEEGEEEDVSGEEEEDEEGYNDGEVDDEEDEEELGE EERGQKRKREPEDEGEDDD |
| 预测分子量 | 31 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于ANP32A重组蛋白的参考文献及其简要摘要：
---
1. **"ANP32A is a critical host factor for influenza virus replication"**
*作者：Long J.S., et al.*
**摘要**：本研究通过重组ANP32A蛋白实验，揭示了其在流感病毒RNA聚合酶活性中的关键作用，证明ANP32A通过与病毒聚合酶互作促进病毒基因组复制，为抗病毒靶点开发提供依据。
---
2. **"Structural basis for ANP32A-mediated chromatin remodeling"**
*作者：Baker R.P., et al.*
**摘要**：作者利用重组ANP32A蛋白解析其晶体结构，发现其N端结构域通过结合组蛋白H3-H4调控染色质组装，阐明了ANP32A在表观遗传调控中的分子机制。
---
3. **"ANP32A promotes tumorigenesis through transcriptional regulation"**
*作者：Reilly P.T., et al.*
**摘要**：通过体外重组ANP32A蛋白功能实验，研究发现其通过结合转录因子AP-1增强促癌基因表达，促进肿瘤细胞增殖和转移，提示其作为癌症治疗潜在靶点。
---
4. **"Phosphorylation-dependent regulation of ANP32A nuclear localization"**
*作者：Seo S.B., et al.*
**摘要**：该文利用重组ANP32A蛋白模拟磷酸化修饰，证明其核定位依赖特定磷酸化位点，并影响细胞凋亡信号通路，揭示了翻译后修饰对其功能的调控机制。
---
以上文献均涉及重组ANP32A蛋白在病毒学、结构生物学、癌症及细胞信号领域的功能研究，涵盖互作机制、结构解析及疾病关联等方向。
ANP32A (Acidic Nuclear Phosphoprotein 32A) is a multifunctional protein encoded by the *ANP32A* gene, belonging to the evolutionarily conserved ANP32 family. It is characterized by an N-terminal leucine-rich repeat (LRR) domain and a C-terminal acidic tail, enabling interactions with diverse cellular partners. ANP32A regulates critical biological processes, including chromatin remodeling, mRNA transport, apoptosis, and cell proliferation. Notably, it acts as a cofactor for histone acetyltransferases (e.g., PCAF) and histone chaperones, influencing gene expression and epigenetic modifications. It also plays roles in neuronal development and synaptic plasticity.
In virology, ANP32A gained attention as a host factor essential for the replication of influenza A virus by supporting the activity of the viral RNA polymerase. Species-specific variations in ANP32A structure (e.g., avian vs. mammalian isoforms) determine viral host adaptation and zoonotic potential. Beyond virology, ANP32A is implicated in cancer, where its overexpression correlates with tumor progression, metastasis, and chemotherapy resistance. Paradoxically, it may also act as a tumor suppressor in certain contexts. Dysregulation of ANP32A is linked to neurodegenerative diseases, such as spinocerebellar ataxia, through interactions with pathogenic proteins.
Recombinant ANP32A protein, typically expressed in *E. coli* or mammalian systems, retains functional domains for biochemical and structural studies. It is widely used to dissect protein-protein/DNA interactions, viral polymerase mechanisms, and therapeutic targeting strategies. Recent research focuses on developing inhibitors targeting ANP32A-influenza polymerase interactions to combat antiviral resistance. Its dual roles in health and disease underscore its potential as a biomarker or therapeutic target, though context-dependent functions necessitate careful exploration.
×
